Background The use of psychotropic drugs, namely those with an antidepressant profile (ADs), is a mandatory part of an integrated treatment of psychiatric disorders among cancer patients. We aimed to synthetize the most relevant data emerging from published studies to provide tips about the use of ADs in oncology. Design A search was made of the major databases over the last 30 years (Embase/Medline, PsycLIT, PsycINFO, the Cochrane Library), including narrative reviews, systematic reviews and meta-analyses summarizing the results from observational studies and randomized clinical trials assessing effectiveness, safety profile, interactions, contraindications and use of ADs in oncology with regard to both psychiatric (depressive spectrum, stress-related, anxiety disorders) and cancer-related symptoms (e.g. pain, hot flashes and fatigue). Results The weight of evidence supports the efficacy of ADs for more severe major depression in individuals with cancer and as an adjuvant treatment in cancer-related symptoms, although the methodological limitations of reported randomized controlled trials do not permit definite conclusions. Data also indicate that there should be caution in the use of ADs in cancer patients in terms of their safety profile and potential clinically significant interactions with other prescribed medications. Practical recommendations that have been made for the use of ADs in cancer patients, in the context of a multimodal approach to depression treatment, have been summarized here. Conclusions ADs are a relatively safe and effective treatment for more severe major depression in cancer patients. However, more research is urgently needed regarding the efficacy of ADs in different cancer types and cancer settings, their interactions with anticancer agents and their additive benefit when integrated with psychosocial interventions.

中文翻译：

---

抗抑郁药在肿瘤学中的应用：肿瘤学家的回顾和实用技巧。

背景技术使用精神药物，即具有抗抑郁特征的药物，是癌症患者精神疾病综合治疗的强制性部分。我们旨在综合已发表研究中出现的最相关的数据，以提供有关在肿瘤学中使用AD的提示。设计在过去30年中对主要数据库（Embase / Medline，PsycLIT，PsycINFO，Cochrane图书馆）进行了搜索，包括叙述性评论，系统评价和荟萃分析，汇总了观察性研究和评估疗效的随机临床试验的结果在精神病学（抑郁谱，压力相关，焦虑症）和癌症相关症状（例如疼痛，潮热和疲劳）方面，AD的安全性，相互作用，禁忌症和在肿瘤学中的使用。结果尽管有报道的随机对照试验的方法学上的局限性尚不能得出明确的结论，但有力的证据支持ADs在患有癌症的个体中更严重的严重抑郁症以及作为癌症相关症状的辅助治疗的有效性。数据还表明，就癌症患者的安全性以及与其他处方药的潜在临床意义重大相互作用而言，在癌症患者中使用AD时应谨慎行事。本文总结了在多模式抑郁症治疗的背景下在癌症患者中使用AD的实用建议。结论AD是治疗癌症患者更严重的严重抑郁症的相对安全有效的方法。然而，